Ticker Details
Aclaris Therapeutics, Inc. Aclaris Therapeutics Inc is a clinical-stage specialty pharmaceutical company which focuses on identifying, developing and commercializing differentiated drugs to address significant unmet needs in dermatology.
IPO Date:	October 7, 2015
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$943.54M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.35 | 3.76%
Avg Daily Range (30 D):	$0.21 | 3.69%
Avg Daily Range (90 D):	$0.17 | 3.42%

Institutional Daily Volume
Avg Daily Volume:	.78M
Avg Daily Volume (30 D):	1.68M
Avg Daily Volume (90 D):	1.42M

Trade Size
Avg Trade Size (Sh.):	157
Avg Trade Size (Sh.) (30 D):	116
Avg Trade Size (Sh.) (90 D):	109

Institutional Trades
Total Institutional Trades:	1,304
Avg Institutional Trade:	$1.62M
Avg Institutional Trade (30 D):	$1.8M
Avg Institutional Trade (90 D):	$1.72M
Avg Institutional Trade Volume:	.17M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.49M
Avg Closing Trade (30 D):	$.97M
Avg Closing Trade (90 D):	$1.47M
Avg Closing Volume:	163.35K

News

Mar 20, 2026 @ 3:00 PM Aclaris Therapeutics Announces Poster on Results f... Source: Aclaris Therapeutics, Inc.

Feb 24, 2026 @ 12:00 PM Aclaris Therapeutics Initiates Phase 1b Proof-of-C... Source: Na

Nov 25, 2025 @ 1:00 PM Aclaris Therapeutics to Participate in the Piper S... Source: Will Roberts

Sep 9, 2025 @ 11:00 AM Aclaris Therapeutics Announces Late-Breaking Abstr... Source: Aclaris Therapeutics

Aug 27, 2025 @ 12:00 PM Aclaris Therapeutics to Participate in Two Septemb... Source: Will Roberts

Financials
	TTM	Q2 2026	Q1 2026
Basic EPS	$-.58	$-.15	$-.15
Diluted EPS	$-.58	$-.15	$-.15
Revenue	$8.22M	$1.63M	$2M
Gross Profit	$6.54M	$1.41M	$1.6M
Net Income / Loss	$-75.74M	$-21.51M	$-19.82M
Operating Income / Loss	$-86.31M	$-24.24M	$-22.19M
Cost of Revenue	$1.68M	$.22M	$.4M
Net Cash Flow	$-6.24M	$-9.49M	$8.7M
PE Ratio